Next Generation Cancer Diagnostics and Monitoring Technologies
Imagine the potential of diagnostics enabling personalized cancer care
Oncobit CE marks its first products
Oncobit has CE marked its first product to enable personalized cancer care. Oncobit PM BRAFV600 allows the sensitive and specific detection of BRAFV600 mutations in the patient’s blood over time and can be utilized for the monitoring of treatment response, minimal residual disease, and disease recurrence of melanoma.
We are very excited that Hiro Yamada joined our team in May as a Research Associate. Hiro has worked for 10 years as research coordinator and lab manger in the US and Switzerland and will strengthen our laboratory team with his extensive expertise in biochemistry and molecular biology techniques.
Oncobit is part of the Swiss National Startup Team 2022
We are thrilled to be one of ten Venture Leaders Medtech 2022. During the kick-off event, our CEO Claudia Scheckel was selected to serve as team captain during the roadshow in Boston in June 2022.
Oncobit obtains ISO 13485 certification
Oncobit obtains ISO 13485 certification for the design, development and manufacturing of IVD systems to detect and monitor genomic alterations in cancer patients. The certification of Oncobit's quality management system is a major milestone and critical for the launch of Oncobit's products on the European market.
Oncobit wins Venture Kick
By passing the third stage of Venture Kick, Oncobit receives 150'000 CHF to advance personalized cancer care.
Oncobit Team Expansion
Dr. Elisa Bellini as Senior Scientist and Dr. Barbara Geissmann as Senior Computer Scientist officially join the Oncobit team. Both are experts in their respective fields, and previously worked closely with Oncobit through an Innosuisse project.
Oncobit passes Second Stage of Venture Kick
Oncobit successfully passes the second stage of Venture Kick and wins CHF 40’000.
Reinforcement of Team and Relocation of Oncobit Offices
Oncobit moves into its own offices in Schlieren and expands its software team by welcoming Lucas Kohler, joining from ETH, where he obtained a Master in Statistics, as well as Dr. Stephany Orjuela, who just completed her PhD in bioinformatics.
Oncobit Closes CHF 2.3 million Seed Financing Round
The MedTech startup based in Zurich secures more than CHF 2.3 million in seed financing. With Dr. Simona Morello (Business Developer) and Dr. Elena Clementi (Product Developer) two new specialists will strengthen the Oncobit team to further develop its products and obtain regulatory approval.
Oncobit Attends Prestigious Innosuisse Market Validation Camp
Oncobit is part of the Innosuisse internalisation camp spring cohort, to move forward with market validation in the US.
Oncobit Passes First Stage of Venture Kick
Oncobit successfully passes the first stage of Venture Kick and wins CHF 10’000.
Oncobit Receives USZ Health Innovation Hub Support
Oncobit is accepted into the innovation program of the Health Innovation Hub from the University Hospital Zurich and receives CHF 200’000.
Oncobit Ranks in the Top-5 of the Swiss AI Award
Oncobit is selected to be under the Top-5 of the first Swiss AI Award.
Oncobit’s tests provide critical decision support in the treatment and monitoring of advanced melanoma patients.
Prof. Dr. med. Reinhard Dummer, Department of Dermatology USZ, Head of the Skin tumor center, Expert for the Comprehensive Cancer Center Zürich